Trending Now
Business
Endo: A Major Seal Of Approval From Merck?
In the past I have been extremely bearish on Endo International (ENDP). Drug companies like Endo, Mallinckrodt (MNK) and Insys (INSY) have seen their...
Novartis’s Kymriah Is Coming To America
Gilead (NASDAQ:GILD) acquired Kite Pharma for $12 billion, and the novel CAR-T therapy received FDA approval within months. For a while, it seemed like...
Lifestyle today
Entertainment
Washington AG Bob Ferguson Tweaking So Hard, BMF’s Lamar Is Taking Pictures
President Trump threw down the gauntlet in 2017, promising to bring opioid manufacturers to justice for their role in the opioid epidemic....
Mohawk Tribe Seeks To Dismiss Allergan Patent Case; Where Is Sherrod Brown?
The fight to protect Allergan's (AGN) Restasis patents is heating up. Friday the St. Regis Mohawk Tribe filed to have Mylan's (MYL) challenge to...
Shkreli’s Lawyer Convicted Of Helping Pharma Bro Defraud Investors
Evan Greebel, former lawyer for companies run by Martin Skhreli could be headed to prison. A jury convicted him of helping "Pharma Bro" defraud...
Trump And The GE: Maria Chappelle Nadal Video That Triggered Claire McCaskill
The mid-term elections are here and several senate seats are up for grabs. The battle between Missouri Senator Claire McCaskill and Attorney General Josh...
A Successful Opioid Settlement Could Put Endo In Play
In my opinion, Endo International (ENDP) is one of the more perplexing names in the stock market. Just when you think you have a...
Ric Flair: ‘Georgia Will Kick Alabama’s ________’
The Georgia Bulldogs and Alabama Crimson Tide lock horns tonight in order to crown college football's national champion. Forget what the University Of Central...
Flattening Yield Curve Portends Another Recession, Like ‘Shock Exchange’ Predicted
After a decade of money-printing that has spiked asset prices like stocks and real estate, the U.S. economy appears to be on solid footing....
Citron Is Right About Endo’s Upside
Endo International (ENDP) is still one of the market's most frustrating, confounding stocks. The stock hit a 52-week high of over $18 in the...
























































































































